Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-κB activity

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3586-3595

  Cicek, Muzaffer ^a   Fukuyama, Ryuichi ^a   Welch, Danny R ^b   Sizemore, Nywana ^a   Casey, Graham ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER METASTASIS SUPPRESSOR 1 PROTEIN; COMPLEMENTARY DNA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BREAST CANCER; BREAST CANCER METASTASIS SUPPRESSOR 1 GENE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOT HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; URINARY PLASMINOGEN ACTIVATOR;

EID: 18144425158     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3139     Document Type: Article

References (57)

1. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000;60:2764-9.
2. Meehan WJ, Welch DR. Breast cancer metastasis suppressor 1: update. Clin Exp Metastasis 2003;20:45-50.
3. Meehan WJ, Samant RS, Hopper JE, et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 2004;279:1562-9.
4. Quigley JP. Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator. Cell 1979;17:131-41.
5. Liotta LA, Goldfarb RH, Brundage R, et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
6. Alexander CM, Werh Z. Extracellular matrix degradation. New York: Plenum Press; 1991. p. 255-302.
7. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
8. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
9. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998;94:353-62.
10. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989;2:1049.
11. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53;2513-21.
12. Hayes DF, Rast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
13. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003;21:1022-8.
14. Look M, van Putten W, Duffy M, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003;90:538-48.
15. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
16. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002;277:3150-7.
17. Karashima T, Sweency P, Kamal A, et al. Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003;9:2786-97.
18. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988;242:540-6.
19. Beg AA, Ruben SM, Scheinman RI, et al. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev 1992;6:1899-913.
20. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995;80:529-32.
21. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol Cell Biol 1945;15:2809-18.
22. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485-8.
23. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 1995;14:2876-83.
24. Li ZW, Chu W, Hu Y. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999;189:1839-45.
25. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
26. Rayet B, Gelinas C. Aberrant rel/nfkh genes and activity in human cancer. Oncogene 1999;18:6938-47.
27. Huang S, Deguzman A, Bucana CD, Fidler IJ. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573-81.
28. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334-9.
29. Lind DS, Hochwald SN, Malaty J. Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001;130:363-9.
30. Orlowski RZ, Baldwin AS Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
31. Lin A, Karin M. NF-κB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14.
32. Gilmore TD. The Rel/NF-κB/IκB signal transduction pathway and cancer. Cancer Treat Res 2003;115:241-65.
33. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990;50:717-21.
34. Welch DR, Bisi JE, Miller BE, et al. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991;47:227-37.
35. Welch DR, Chen P, Miele ME, et al. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 1994;9:255-62.
36. Samant RS, Seraj MJ, Saunders MM, et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 2000;18:683-93.
37. Shevde LA, Samant RS, Goldberg SF, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002;273:229-39.
38. Yang CH, Murti A, Pfeffer SR, et al. Interferon α/β promotes cell survival by activating nuclear factor κB through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001;276:13756-61.
39. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000;43:155-60.
40. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001;61:1367-74.
41. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
42. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
43. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
44. Gilmore TD. Introduction: the Rel/NF-κB signal transduction pathway. Semin Cancer Biol 1997;8:61-2.
45. Gapuzan ME, Yufit PV, Gilmore TD. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene 2002;21:2484-92.
46. Yan C, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-κB binding to the promoter as a consequence of IκBα-induced block of p65/p50 nuclear translocation. J Biol Chem 2001;276:1164-72.
47. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001;293:1653-7.
48. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21:7065-77.
49. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625-36.
50. Baek SH, Ohgi KA, Rose DW, et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-κB and β-amyloid precursor protein. Cell 2002;110:55-67.
51. Samant RS, Debies MT, Shevde LA, Verderame MF, Welch DR. Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1). Int J Cancer 2002;97:15-20.
52. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
53. Quax PH, Pedersen N, Masucci MT. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991;2:793-803.
54. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993;90:5021-5.
55. Needham GK, Sherbet GV, Farndon JR, Harris AL. Binding of urokinase to specific receptor sites on human breast cancer membranes. Br J Cancer 1987;55:13-6.
56. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000;61:1-12.
57. Tetu B, Brisson J, Lapointe H, Bernard P. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 1998;29:979-85.